WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates
SHANGHAI and SEOUL, South Korea, July 8, 2022 /PRNewswire/ -- WuXi XDC, a global leading CRDMO (Contract Research, Development and Manufacturing Organization) dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugates (ADC), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in AbTis'...
Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 8, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic...
A new study confirms: EMDR therapy can be done effectively online with remotEMDR
WORCESTER, England, July 8, 2022 /PRNewswire/ -- A first of its kind academic research confirms that conducting online EMDR therapy using remotEMDR, the world's leading platform for online EMDR therapy, is safe, effective, efficient, and relevant.   Watch remotEMDR's video to find out more. Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based psychotherapy that has been...
Billion-Euro Market Biotechnology: Exyte Builds mRNA Competence Center for WACKER in Halle
Exyte named as general contractor (EPCQ contract partner) Project is part of the German government's program to prepare for future pandemics Implementation in less than 24 months thanks to ExyCell® modular system Lighthouse project for the strategic growth segment of Biopharma and Life Sciences at Exyte Biotechnology and personalized medicine drive...
HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol
Dr. Geoff Nichol, M.B., Ch.B., M.B.A., joins HaemaLogiX's Board of Directors as Non-Executive Director, bringing nearly 30 years of global drug development experience Past achievements include approval of Augmentin BID for adults and children, plus foundational clinical development of breakthrough cancer immunotherapy checkpoint inhibitors, Yervoy and Optivo SYDNEY, July 8, 2022 /PRNewswire/ -- HaemaLogiX Ltd, a...
Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine
Insilico and its collaborators scoured massive datasets and found genes relevant to ALS through PandaOmics™, Insilico's proprietary AI-driven target identification engine. 28 targets were identified from CNS and diMN samples; for 18 targets (64%), suppression moderately or strongly rescued neurodegeneration. The collaborative study was led by Insilico with support from Answer ALS and researchers at Johns Hopkins University...
United Imaging To Feature Leaders of Choice Program, Innovative Purchasing Models, and World’s-First Equipment at AHRA in Phoenix
Leaders of Choice is the educational program United Imaging and AHRA Announced Jointly in May. HOUSTON, July 7, 2022 /PRNewswire/ -- United Imaging confirmed that its Houston-based U.S. leadership team will be on hand in Phoenix for the AHRA (Association for Medical Imaging Management) Annual Meeting starting this weekend. The two organizations announced the Leaders of Choice program...
SunHo Announces First Patient Dosed in Phase 1/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972
NANJING, China, July 7, 2022 /PRNewswire/ -- SunHo BioPharmaceutical Co., Ltd. ("SunHo"), a clinical-stage leading biopharma in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IAP0971 (PD1-IL15 immunocytokine) and IAE0972 (EGFR-IL10 immunocytokine), two first-in-class immunocytokines developed in-house for the treatment of locally-advanced or metastatic malignant tumors have entered Phase 1/2 clinical trials. The first patient has...
Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines
GUANGZHOU, China, July 7, 2022 /PRNewswire/ -- Recently, Zhiyi Biotech announced that it has raised $15 million in its B++ funding round. The funds will be used to boost the clinical development of the company's live biotherapeutic products (LBPs) pipelines. It's worth mentioning that Zhiyi has successfully completed a total of $45...
ASUS and Tan Tock Seng Hospital co-develop an AI-based tool to improve the accuracy and efficiency of diagnosis in blood diseases
Both parties inked an MOU to accelerate integration of AI-powered solutions into clinical care, to support Singapore's healthcare transformation SINGAPORE, July 7, 2022 /PRNewswire/ -- ASUS and Tan Tock Seng Hospital (TTSH) inked a three-year Memorandum of Understanding (MOU) earlier today to formalise their collaborative efforts on building a more robust healthcare system to meet the evolving needs of patients. Since...
